Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 avr. 2025 08h30 HE | Source: AP Biosciences

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 29, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...
22 avr. 2025 08h30 HE | Source: AP Biosciences

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

TAIPEI, Taiwan, April 22, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific...
21 avr. 2025 23h37 HE | Source: AP Biosciences

UPDATE -- AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...
21 avr. 2025 08h30 HE | Source: AP Biosciences

AP Bioscience to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...